Skip to main content

Ventavis FDA Approval History

FDA Approved: Yes (First approved December 29, 2004)
Brand name: Ventavis
Generic name: iloprost
Dosage form: Inhalation Solution
Company: CoTherix, Inc.
Treatment for: Pulmonary Arterial Hypertension

Ventavis (iloprost) inhalation solution is synthetic analogue of prostacyclin PGIB2B indicated for the treatment of pulmonary arterial hypertension.

Development timeline for Ventavis

Dec 29, 2004Approval Ventavis CoTherix, Inc. - Treatment for Pulmonary Arterial Hypertension
Sep  8, 2004CoTherix, Inc. Announces Priority Review Designation by the FDA for Ventavis NDA
Jul  1, 2004CoTherix, Inc. Announces Filing of Ventavis NDA

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.